A dermocosmetic regimen is able to mitigate skin sensitivity induced by a retinoid‐based fixed combination treatment for acne: Results of a randomized clinical trial
Journal of Cosmetic Dermatology · 2024
DOI: 10.1111/jocd.16120 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Amir Khammari und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nantes University, CHU Nantes, CIC 1413, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, Nantes, France. Hauptthemen laut MEDLINE: Dermatologic Agents, Acne Vulgaris. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Topical retinoids cause retinoid‐induced skin discomfort (RISD) mainly during the first weeks of use leading to noncompliance and premature treatment discontinuation. A dermocosmetic (DC) may help to reduce treatment‐related signs and symptoms and improve adherence.
Objectives
To assess the benefit of a DC regimen compared to a routine skin care regimen (RC) by reducing RISD signs and symptoms induced by a retinoid/benzoyl peroxide fixed‐drug combination in subjects with acne. Materials and Methods Double‐blind, randomized, comparative study in subjects ≥16 years with mild to moderate acne candidates to a topical adapalene/BPO fixed drug combination (A/BPO). Evaluations took place at Day 0, 7, 14, 28, and 84 and included erythema, desquamation, burning, itching and stinging and RISD (SD, a composite score of local treatment‐related signs and symptoms and acne severity. Subjects used daily the DC or RC together with the fixed combination for 84 days.
Results
Eighty‐eight subjects were included, the mean age was 21 years; 84% were females. At Day 0 the SD score was 0.8 in both groups. A statistically significant difference in terms of skin sensitivity with DC compared to RC (1.6 points, vs. 2.4 points p < 0.05) was observed at Day 14. Clinical sign and symptom scores were more reduced with DC than with RC at all time points. Acne severity improved in both groups.
Conclusion
DC significantly reduces A/BPO‐related RISD compared to RC, especially during the first 14 days of treatment, without interfering with the clinical efficacy of the treatment, thus helping to maintain treatment adherence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Nantes University, CHU Nantes, CIC 1413, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, Nantes, France.
- La Roche-Posay Laboratoire Dermatologique, Levallois-Perret, France.
- Nantes University, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, Nantes, France.
ORCID-Profile: Delphine Kerob
Zitieren
APA
Khammari, A., Kerob, D., Demessant, A. L., Nioré, M., & Dréno, B. (2024). A dermocosmetic regimen is able to mitigate skin sensitivity induced by a retinoid‐based fixed combination treatment for acne: Results of a randomized clinical trial. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16120
Vancouver
Khammari A, Kerob D, Demessant AL, Nioré M, Dréno B. A dermocosmetic regimen is able to mitigate skin sensitivity induced by a retinoid‐based fixed combination treatment for acne: Results of a randomized clinical trial. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16120
BibTeX
@article{Khammari2024,
author = {Khammari, Amir and Kerob, Delphine and Demessant, Ann' Laure and Nioré, Margot and Dréno, Brigitte},
title = {A dermocosmetic regimen is able to mitigate skin sensitivity induced by a retinoid‐based fixed combination treatment for acne: Results of a randomized clinical trial},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
doi = {10.1111/jocd.16120}
}
EUVIMED